$PMVP
PMV Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015767 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.709M $6.423M $6.783M
YoY Change -3.81% 19.25% 62.66%
% of Gross Profit
Research & Development $13.67M $11.46M $11.84M
YoY Change 49.16% 49.56% 57.81%
% of Gross Profit
Depreciation & Amortization $74.00K $82.00K $84.00K
YoY Change -7.5% 15.49% 6.33%
% of Gross Profit
Operating Expenses $19.38M $17.89M $18.62M
YoY Change 28.34% 37.05% 59.49%
Operating Profit -$19.38M -$17.89M -$18.62M
YoY Change 28.34% 37.05% 59.49%
Interest Expense $1.124M $604.0K $229.0K
YoY Change 1001.96% 434.51% 76.15%
% of Operating Profit
Other Income/Expense, Net $1.137M $573.0K $188.0K
YoY Change 982.86% 225.57% 147.37%
Pretax Income -$18.24M -$17.31M -$18.43M
YoY Change 21.65% 34.47% 58.92%
Income Tax -$9.000K -$2.000K $2.000K
% Of Pretax Income
Net Earnings -$18.23M -$17.31M -$18.43M
YoY Change 21.44% 34.46% 58.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.38 -$0.41
Diluted Earnings Per Share -$0.40 -$379.8K -$405.4K
COMMON SHARES
Basic Shares Outstanding 45.62M 45.57M 45.47M
Diluted Shares Outstanding 45.62M 45.57M 45.47M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $258.9M $277.4M $294.8M
YoY Change -20.66% -18.35% -15.39%
Cash & Equivalents $99.85M $87.09M $115.8M
Short-Term Investments $159.0M $190.3M $179.0M
Other Short-Term Assets $6.319M $4.431M $5.047M
YoY Change 7.03% -6.34% 44.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $265.2M $281.9M $288.0M
YoY Change -15.43% -12.76% -14.02%
LONG-TERM ASSETS
Property, Plant & Equipment $9.966M $8.721M $5.238M
YoY Change 614.92% 596.01% 249.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $11.77M
YoY Change -100.0% -100.0% -30.34%
Other Assets $307.0K $308.0K $221.0K
YoY Change 40.83% 53.23% -78.42%
Total Long-Term Assets $19.81M $18.70M $26.97M
YoY Change -35.32% -43.04% 39.06%
TOTAL ASSETS
Total Short-Term Assets $265.2M $281.9M $288.0M
Total Long-Term Assets $19.81M $18.70M $26.97M
Total Assets $285.0M $300.6M $315.0M
YoY Change -17.2% -15.55% -11.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.826M $3.348M $4.864M
YoY Change 277.62% 41.33% 288.5%
Accrued Expenses $6.436M $7.652M $6.563M
YoY Change -4.51% 71.65% 69.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.66M $11.38M $11.69M
YoY Change 36.12% 51.69% 101.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.14M $12.21M $11.48M
YoY Change 13.76% 15.65% 3726.67%
Total Long-Term Liabilities $12.14M $12.21M $11.48M
YoY Change 13.76% 15.65% 3726.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.66M $11.38M $11.69M
Total Long-Term Liabilities $12.14M $12.21M $11.48M
Total Liabilities $23.79M $23.59M $23.17M
YoY Change 23.72% 30.62% 279.75%
SHAREHOLDERS EQUITY
Retained Earnings -$221.7M -$203.5M -$186.2M
YoY Change 48.43% 51.44% 53.24%
Common Stock $483.9M $481.5M $478.7M
YoY Change 2.03% 1.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.2M $277.0M $291.8M
YoY Change
Total Liabilities & Shareholders Equity $285.0M $300.6M $315.0M
YoY Change -17.2% -15.55% -11.11%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$18.23M -$17.31M -$18.43M
YoY Change 21.44% 34.46% 58.88%
Depreciation, Depletion And Amortization $74.00K $82.00K $84.00K
YoY Change -7.5% 15.49% 6.33%
Cash From Operating Activities -$16.76M -$13.68M -$18.00M
YoY Change 35.18% 47.96% 39.48%
INVESTING ACTIVITIES
Capital Expenditures -$2.050M -$3.500M $796.0K
YoY Change 309.18% 651.07% 563.33%
Acquisitions
YoY Change
Other Investing Activities $31.56M -$11.78M -$38.03M
YoY Change -16539.06% 16.81% -72.79%
Cash From Investing Activities $29.51M -$15.28M -$38.83M
YoY Change -4358.73% 44.82% -72.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.000K 276.0K 128.0K
YoY Change -98.06% -78.06% -20.99%
NET CHANGE
Cash From Operating Activities -16.76M -13.68M -18.00M
Cash From Investing Activities 29.51M -15.28M -38.83M
Cash From Financing Activities 6.000K 276.0K 128.0K
Net Change In Cash 12.76M -28.68M -56.70M
YoY Change -199.83% 54.73% -62.86%
FREE CASH FLOW
Cash From Operating Activities -$16.76M -$13.68M -$18.00M
Capital Expenditures -$2.050M -$3.500M $796.0K
Free Cash Flow -$14.71M -$10.18M -$18.79M
YoY Change 23.64% 15.95% 44.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Variable Lease Cost
VariableLeaseCost
395000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
16911000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9670000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001699382
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39539
dei Entity Registrant Name
EntityRegistrantName
PMV PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3218129
dei Entity Address Address Line1
EntityAddressAddressLine1
8 Clarke Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Cranbury
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08512
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
642-6670
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
PMVP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45622610
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87090000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172467000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
190344000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
124696000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3609000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3301000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
281865000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
301286000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8721000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10060000
CY2021Q4 us-gaap Assets
Assets
331568000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3348000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3189000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7652000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
221000
CY2022Q2 us-gaap Assets
Assets
300564000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8627000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
403000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11383000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12219000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12211000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10790000
CY2022Q2 us-gaap Liabilities
Liabilities
23594000
CY2021Q4 us-gaap Liabilities
Liabilities
23009000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45622610
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45622610
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45433684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45433684
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
481462000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
476363000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203469000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167726000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1023000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-78000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
276970000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
308559000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300564000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
331568000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11462000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7664000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23297000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15163000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6423000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5386000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17885000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
13050000
us-gaap Operating Expenses
OperatingExpenses
36503000
us-gaap Operating Expenses
OperatingExpenses
24723000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7664000
us-gaap Operating Expenses
OperatingExpenses
36503000
us-gaap Operating Expenses
OperatingExpenses
24723000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17885000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13050000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13206000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9560000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17885000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13050000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
604000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
113000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
832000
CY2021Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
63000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-72000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
11000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
573000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
176000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
760000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
252000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17312000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12874000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35743000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24472000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
us-gaap Net Income Loss
NetIncomeLoss
-24476000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-357000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
20000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17667000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12854000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36688000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24469000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45571067
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45070104
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45518845
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44928518
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
162000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
627000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36503000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24723000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
604000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
832000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
241000
CY2022Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-31000
CY2021Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
63000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
11000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
573000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
176000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
760000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
252000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17312000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24472000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
20000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-945000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36688000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24469000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45571067
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45070104
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45518845
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44928518
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
162000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
627000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11602000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2021Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
1256000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
308559000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2177000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18433000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-588000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291843000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11602000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1150000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2022Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
276000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2518000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
348295000
CY2021Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
1256000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
337847000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
308559000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2177000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18433000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-588000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291843000
CY2022Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
276000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2518000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-357000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
276970000
us-gaap Profit Loss
ProfitLoss
-24476000
us-gaap Share Based Compensation
ShareBasedCompensation
4695000
us-gaap Share Based Compensation
ShareBasedCompensation
1777000
us-gaap Depreciation
Depreciation
166000
pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
180000
pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
314000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
88000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
308000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
570000
pmvp Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-1612000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1342000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
762000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-975000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-434000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31677000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22145000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4296000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
586000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
149223000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
185224000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
99415000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
35360000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54104000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150450000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
404000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1418000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1418000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-85377000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-171177000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
173289000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361422000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87912000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-357000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
276970000
us-gaap Profit Loss
ProfitLoss
-35743000
us-gaap Profit Loss
ProfitLoss
-24476000
us-gaap Share Based Compensation
ShareBasedCompensation
4695000
us-gaap Share Based Compensation
ShareBasedCompensation
1777000
us-gaap Depreciation
Depreciation
166000
us-gaap Depreciation
Depreciation
150000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-126000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-332000
pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
180000
pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
314000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
88000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
308000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
570000
pmvp Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-1612000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1342000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-975000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-434000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22145000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4296000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
586000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
149223000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
35360000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54104000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150450000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
404000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1418000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1418000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-85377000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-171177000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
173289000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361422000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87912000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190245000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1501000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31677000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203469000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
277434000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203469000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
277434000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
190245000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1501000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">are not limited to, research and development costs, accrued research and development costs and related prepaid expenses and stock-based compensation. Actual results could differ materially from those estimates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a “Public Health Emergency of International Concern,” which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
72000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
165000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
126000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
332000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
822000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">are not limited to, research and development costs, accrued research and development costs and related prepaid expenses and stock-based compensation. Actual results could differ materially from those estimates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a “Public Health Emergency of International Concern,” which continues to spread throughout the world. The outbreak has adversely impacted global commercial activity and contributed to significant volatility in financial markets. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
72000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
165000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
126000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
332000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
822000
us-gaap Variable Lease Cost
VariableLeaseCost
395000
us-gaap Variable Lease Cost
VariableLeaseCost
311000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
310645000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
81000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
310567000
CY2022Q2 us-gaap Cash
Cash
3317000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
83773000
CY2021Q4 us-gaap Cash
Cash
3508000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
168960000
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
190344000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
190344000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
141607000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
124696000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
16911000
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Operating Lease Cost
OperatingLeaseCost
1042000
us-gaap Operating Lease Cost
OperatingLeaseCost
668000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
275140000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1030000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274117000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
310645000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
81000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
310567000
CY2022Q2 us-gaap Cash
Cash
3317000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
83773000
CY2021Q4 us-gaap Cash
Cash
3508000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
168960000
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
190344000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
141607000
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10755000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4958000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2034000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1868000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8721000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
198000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
192000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10755000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4958000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2034000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1868000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8721000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2022Q2 us-gaap Depreciation
Depreciation
82000
CY2021Q2 us-gaap Depreciation
Depreciation
71000
us-gaap Depreciation
Depreciation
166000
us-gaap Depreciation
Depreciation
150000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3797000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
135000
CY2022Q2 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4901000
CY2021Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4734000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7652000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8627000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
us-gaap Variable Lease Cost
VariableLeaseCost
311000
CY2022Q2 us-gaap Depreciation
Depreciation
82000
CY2021Q2 us-gaap Depreciation
Depreciation
71000
us-gaap Depreciation
Depreciation
166000
us-gaap Depreciation
Depreciation
150000
CY2022Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2510000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3797000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
135000
CY2022Q2 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4901000
CY2021Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4734000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8627000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
530000
us-gaap Operating Lease Cost
OperatingLeaseCost
1042000
us-gaap Operating Lease Cost
OperatingLeaseCost
668000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
198000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
192000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
530000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
511000
CY2022Q2 us-gaap Lease Cost
LeaseCost
728000
CY2021Q2 us-gaap Lease Cost
LeaseCost
703000
us-gaap Lease Cost
LeaseCost
979000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9670000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10060000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
403000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12211000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11193000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M9D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y7D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
-750000
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
354000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10314000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
17334000
CY2022Q2 us-gaap Lease Cost
LeaseCost
728000
CY2021Q2 us-gaap Lease Cost
LeaseCost
703000
us-gaap Lease Cost
LeaseCost
1437000
us-gaap Lease Cost
LeaseCost
979000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9670000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10060000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
403000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12211000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10790000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12594000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11193000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M9D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y7D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
-750000
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
354000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10314000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsRemainderOfFiscalYear
-1584000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
1833000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
1814000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
1869000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
1925000
CY2022Q2 pmvp Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Four
LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFour
11477000
CY2022Q2 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
17334000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4740000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4740000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12594000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
170472
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.06
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12594000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
530000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
531000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1042000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45622610
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45433684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45433684
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4951680
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4246007
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.33
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
8339
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
8339
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.51
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
170472
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5353193
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
36326000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3009863
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M1D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30124000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25298000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5055106
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5335193
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36326000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5353193
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0148
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0293
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0122
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
530000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
531000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1042000
us-gaap Operating Lease Expense
OperatingLeaseExpense
668000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45622610
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45622610
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45433684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45433684
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4951680
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4246007
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
68506000
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
1363084
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
1267997
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1267997
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.33
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
8339
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
8339
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.51
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M23D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
36326000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3009863
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M1D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30124000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25298000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0148
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0293
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0122
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7700
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2518000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1150000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4695000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1777000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
us-gaap Net Income Loss
NetIncomeLoss
-24476000
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45571067
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45070104
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2518000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1150000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4695000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1777000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
us-gaap Net Income Loss
NetIncomeLoss
-24476000
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45571067
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45070104
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45518845
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44928518
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45518845
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44928518
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79

Files In Submission

Name View Source Status
0000950170-22-015767-index-headers.html Edgar Link pending
0000950170-22-015767-index.html Edgar Link pending
0000950170-22-015767.txt Edgar Link pending
0000950170-22-015767-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmvp-20220630.htm Edgar Link pending
pmvp-20220630.xsd Edgar Link pending
pmvp-ex10_15.htm Edgar Link pending
pmvp-ex31_1.htm Edgar Link pending
pmvp-ex31_2.htm Edgar Link pending
pmvp-ex32_1.htm Edgar Link pending
pmvp-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pmvp-20220630_lab.xml Edgar Link unprocessable
pmvp-20220630_cal.xml Edgar Link unprocessable
pmvp-20220630_pre.xml Edgar Link unprocessable
pmvp-20220630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pmvp-20220630_def.xml Edgar Link unprocessable